Clinical Trials Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Dec 21, 2017; 23(47): 8395-8404
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8395
Table 1 Baseline characteristics of the patients [n = 81, n (%)]
VariablesDexlansoprazoleEsomeprazoleP value
Age (mean ± SD, yr)50.6 ± 13.349.9 ± 12.80.985
Male sex34 (42.0)43 (53.1)0.137
Smoking12 (14.8)9 (11.1)0.483
Alcohol use22 (27.2)22 (27.2)1.000
Ingestion of coffee44 (54.3)36 (44.4)0.209
Ingestion of tea58 (71.6)49 (60.5)0.230
Betel nut4 (4.9)1 (1.2)0.173
Spicy food52 (64.2)51 (63.0)0.870
Sweet food72 (88.9)75 (92.6)0.416
Body mass index25.4 ± 4.824.9 ± 4.40.420
Waist girth88.8 ± 12.288.7 ± 11.40.361
Metabolic syndrome36 (44.4)38 (46.9)0.950
Atypical symptoms
Chest pain38 (46.9)39 (48.1)0.588
Dysphagia20 (24.7)22 (27.2)0.557
Regurgitation of food29 (35.8)31 (38.3)0.561
Nausea26 (32.1)23 (28.4)0.544
Hiccup37 (45.7)44 (54.3)0.300
Foreign body sensation (throat)48 (59.3)40 (49.4)0.301
Foreign body sensation (chest)16 (19.8)16 (19.8)0.604
Hoarseness28 (34.6)28 (34.6)0.604
Throat cleaning44 (54.3)44 (54.3)0.602
Cough38 (46.9)34 (42.0)0.516
Sore throat20 (24.7)20 (24.7)0.604
Dry mouth54 (66.7)52 (64.2)0.590
Bad breath29 (35.8)30 (37.0)0.590
Epigastric pain36 (44.4)45 (55.6)0.197
Epigastric fullness65 (80.2)54 (66.7)0.111
Insomnia36 (44.4)28 (34.6)0.199
Sinusitis7 (8.6)14 (17.3)0.102
Otitis media5 (6.2)5 (6.2)1.000
Sugar97.4 ± 12.597.0 ± 12.80.604
Cholesterol205.3 ± 36.7207.7 ± 35.40.971
Triglyceride121.9 ± 57.2113.7 ± 64.70.284
HDL54.7 ± 18.255.3 ± 14.40.866
LDL127.0 ± 32.7127.5 ± 32.80.942
H. pylori infection
Previous history - no10 (12.3)15 (18.5)0.553
Current infection - no10 (12.3)12 (14.8)0.703
Endoscopic findings
Hiatal hernia10 (12.3)15 (18.5)0.347
GEFV (grade 3 or 4)7 (8.6)8 (9.9)0.521
Esophagitis grade B15 (18.5)13 (16.0)0.678

  • Citation: Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK, Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol 2017; 23(47): 8395-8404
  • URL: https://www.wjgnet.com/1007-9327/full/v23/i47/8395.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v23.i47.8395